Diffuse scleroderma
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A variant of systemic scleroderma characterized by sclerosis of the skin, Raynaud phenomenon, and organ involvement, including pulmonary fibrosis, renal disease, and gastrointestinal tract involvement.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diffuse scleroderma
- Alternative names
- diffuse scleroderma
- Therapeutic area
- Dermatology
- Severity
- Severe
- Dermatology
- Immunology
- Rheumatology
Sources for recorded values
- MONDO ID
- MONDO:0005019
- Parent condition
- MONDO:0005100
Related records
Broader conditions (11)
- Autoimmune disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Human disease
- Immune system disorder
- Integumentary system disorder
- Rheumatic disorder
- Scleroderma
- Skin disorder
- Systemic sclerosis
Trials (308)
- 6-minute Pegboard Ring Test in Patients With Scleroderma
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status.
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- A Clinical Trial for CTD-ILD Treatment
- A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
- A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
- A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
- A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
- A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
- A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
- A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Drugs in development (32)
- Abatacept Phase 2
- Acetylcysteine Phase 2
- Asengeprast Phase 2
- AVID-200 Phase 1
- Belimumab Phase 2
- Belumosudil Phase 2
- Brentuximab vedotin Phase 2
- Cyclophosphamide Phase 3
- Dersimelagon Phase 2
- Etrinabdione Phase 2
- Fipaxalparant Phase 2
- Fludarabine Phase 1
- Fresolimumab Phase 1
- Human immunoglobulin G Phase 2
- Ianalumab Phase 2
- Ifetroban Phase 2
- Lanifibranor Phase 2
- Lenabasum Phase 3
- Methoxsalen Phase 2
- Mycophenolate mofetil Phase 2
Other linked drugs (3)
- Ambrisentan
- Iguratimod
- Methotrexate